Current status of adjuvant chemotherapy for gastric cancer

doi:10.4251/wjgo.v11.i9.679

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 9

This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8433)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

469

WORD

280

HTML

4087

Tables (1-1)

229

Sum=5065

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

587

Download

685

Sum=1272

Publishing Process of This Article

Item

Count

Browse

725

Download

1371

Sum=2096

Sep 15, 2019 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Sep 15, 2019; 11(9): 679-685
Published online Sep 15, 2019. doi: 10.4251/wjgo.v11.i9.679

Table 1 Comparison of guidelines of adjuvant chemotherapy for gastric cancer

Guideline	Methods of adjuvant therapy	Regimen
NCCN	Postoperative chemoradiation (preferred)	5-FU plus irradiation
	Perioperative chemotherapy	ECF
	Perioperative chemotherapy	Modification of ECF
	Postoperative chemotherapy (only after D2 lymph node dissection)	XELOX
		Capecitabine plus cisplatin
ESMO	Perioperative chemotherapy (preferred)	ECF
	Perioperative chemotherapy (preferred)	Modification of ECF
	Postoperative chemotherapy (patients without preoperative therapy)	S-1 monotherapy
		XELOX
	Postoperative chemoradiation (for undertreatment surgery)	5-FU plus irradiation
Japanese	Postoperative chemotherapy	S-1 monotherapy (preferred)
		S-1 plus oxaliplatin
		XELOX

5-FU: 5-Fluorouracil; ECF: Epirubicin, cisplatin, and 5-fluorouracil; ESMO: European Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; XELOX: Capecitabine plus oxaliplatin.

Citation: Kim IH. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 2019; 11(9): 679-685
URL: https://www.wjgnet.com/1948-5204/full/v11/i9/679.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i9.679